AAPL 172.03 +0.12 (+0.07%)MSFT 107.14 +0.57 (+0.53%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 172.03 +0.12 (+0.07%)MSFT 107.14 +0.57 (+0.53%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Cash Flow APLS Quote Apellis Pha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -47 -27 -51
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 1 1 5
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 2 0 1
OtherWorkingCap -1 0 0
OtherNonCashIte 26 0 0
NetCashProvided -19 -26 -47
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 0
DebtIssued 0 0 26
DebtRepayment 0 0 0
CommonStockIssu 0 0 150
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 0 1
NetCashProvided 41 15 197
NetChangeInCash 22 -11 151
CashAtBeginning 14 36 25
CashAtEndOfPeri 36 25 176
Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.